Zika virus outbreaks have been explosive and unpredictable and have led to significant adverse health effects—as well as considerable public anxiety. Significant scientific work has resulted in multiple candidate vaccines that are now undergoing further clinical development, with several vaccines now in phase 2 clinical trials. In this review, we survey current vaccine efforts, preclinical and clinical results, and ethical and other concerns that directly bear on vaccine development. It is clear that the world needs safe and effective vaccines to protect against Zika virus infection. Whether such vaccines can be developed through to licensure and public availability absent significant financial investment by countries, and other barriers discussed within this article, remains uncertain.

While discovered in 1947, Zika virus (ZIKV) remained unimportant and unnoticed until the Yap Island outbreaks in 2007. Even then, it scarcely raised interest and concern quickly abated as the outbreak dwindled without further outbreaks occurring. This situation changed dramatically with the unexpected and large outbreaks that began in 2015 in Brazil—eventually resulting in an estimated 200,000 identified cases. As a result, the world has had to play “catch-up” by rapidly investigating ZIKV immunology, pathophysiology, and its short- and long-term effects, as well as the full spectrum of pathology the virus may cause in different populations.

As of the time of this writing, no effective drug to treat—or vaccine to prevent—Zika infection is licensed and available. Both are needed, yet neither was a priority to scientists or funders until the 2015 outbreaks. Now, as of this writing, some 18 known vaccine candidates are in various stages of preclinical and clinical development. Research funding has been made available, although it is clearly too little, is contributed by too few countries, and may not be sustained. In this regard, recent calls for global funding of new vaccines have proven timely. Lastly, there is still much to be learned about the virus’s mechanism of disease action and how it causes specific pathology across different ages, sexes, medical conditions (eg, pregnancy), and other issues—some undoubtedly yet to be defined.

Despite the large outbreaks in 2015-2016, subsequent years have been relatively quiet in terms of ZIKV. In the United States and US territories, there were over 41,000 cases in 2016, fewer than 1200 cases in 2017, and only 220 cases in 2018. The rest of the world has experienced a similar situation; nonetheless, much of the world is at risk, and the many people who travel are also at risk. Travelers from endemic areas can also introduce ZIKV into the new territories. This scenario begs the question of what the future holds for this virus—continued low-level circulation, outbreaks in new locations, or recurrent outbreaks once population immunity wanes or as the percentage of naive individuals in a population increases? The current unpredictability and lack of future ZIKV outbreaks is a major impediment to creating effective public health policies, disease surveillance, and control measures (including continued clinical vaccine development and studies).

In this review, we will briefly summarize current knowledge about ZIKV and outbreaks, while primarily focusing on issues
related to Zika vaccine development and the current status of these efforts. Finally, we provide a “look ahead” regarding the future of Zika vaccine development.

ZIKA DISEASE/OUTBREAKS

Zika virus was first isolated in Uganda in 1947 in monkeys and spread beyond its historical endemic range in equatorial Africa and Asia to areas of Micronesia in 2013-2014. Up until 2007, when a large epidemic in the Yap Islands resulted in the infection of three-quarters of the approximately 270,000 residents, Zika virus infections remained limited to periodic cases or small-scale epidemics. Since being detected in 2015 in Brazil, with reported cases of congenital malformations and other neurologic disorders linked to Zika virus infection (in French Polynesia and Brazil), Zika virus has spread to many countries in South America, Central America, the Caribbean, and briefly into the United States. On February 1, 2016, the World Health Organization (WHO) declared a Public Health Emergency of International Concern regarding microcephaly, Guillain-Barré syndrome (GBS), and other neurologic conditions associated with the appearance of Zika virus in the Americas. On November 18, 2016, the WHO ended this Public Health Emergency of International Concern. It is projected that nearly 400 million individuals can be potentially infected with Zika virus annually (similar to dengue virus [DENV] infection and burden), as the distribution of the Aedes mosquito species (Aedes aegypti, Aedes albopictus, Aedes polynesiensis, and Aedes hensilli) associated with Zika virus transmission is widespread. A recent study estimates that 22.7 million people in the United States live in areas with active year-round populations of the Aedes mosquito vectors, setting the stage for possible year-round Zika virus transmission. Local transmission has already occurred in US territories in the Caribbean and Pacific regions, demonstrating the unexpected ability of Zika virus to quickly spread to nonepidemic regions. Countries with a documented presence of Zika virus (as of March 2018) are shown in Figure A, and countries suitable for Aedes aegypti and Aedes albopictus are shown in Figure B.

Zika virus infection typically causes no or mild clinical symptoms (such as mild fever, arthralgia, headache, conjunctivitis, rash, muscle and joint pain) in adults and was not considered a major public health threat until recently. These symptoms usually last for 2 to 7 days and have significant similarities with DENV-like disease. The incubation period of Zika virus is not clear but is likely to range from 3 to 12 days. Only 18% of Zika virus infection cases are reported to be symptomatic, and many individuals might never recognize that they have been infected with Zika virus.

Strong evidence now indicates that Zika virus infection can cause severe lethal neurologic malformations, including microcephaly or fetal death (referred to as congenital Zika syndrome). The most severe spectrum of Zika syndrome pathology occurs in the unborn, including musculoskeletal, ocular, craniofacial, genitourinary, pulmonary, and other abnormalities. Zika virus has also been linked to an increased incidence of a potentially life-threatening GBS (an inflammatory autoimmune disorder that affects the peripheral nervous system) in adults, as well as other neurologic abnormalities. Guillain-Barré syndrome occurs at a frequency of 1.1 to 1.8 cases per 100,000 people per year and occurs predominantly in older adults. Since the beginning of the Zika epidemic in French Polynesia in 2013, the incidence of Zika virus-associated GBS has increased by 20-fold, with 42 patients diagnosed with Zika-associated GBS between November 2013 and February 2014. Presently, Brazil is the most affected country, with estimates of 1.5 million cases of Zika virus infection reported since the outbreak began. In 2015, the WHO defined a 19% increase in incidence of GBS in Brazil in comparison with the prior year.
Countries with recent cases of ZIKV

Aedes aegypti and Aedes albopictus

FIGURE. Countries at risk for Zika virus infection. A, The world map shows locations with known Zika virus presence in dark green (current as of March 2018). Data from the Centers for Disease Control and Prevention. B, Countries suitable for Aedes aegypti and Aedes albopictus. Data from Int J Infect Dis. Created with https://mapchart.net.
nonvector transmission, such as sexual transmission from infected males and mother to child transmission, have been well documented. Zika virus has been detected in bodily fluids (eg, semen, urine, saliva, vaginal fluids, breast milk, and tears) following infection; the longest reported period from symptom onset to detection of ZIKV RNA was 9 months following infection in semen from 184 ZIKV-infected men. Data from the largest cohort study to date revealed that infectious ZIKV RNA shedding in semen declines during the first 3 months after symptom onset. Notably, a recently developed synthetic DNA vaccine encoding ZIKV premembrane/membrane (prM) and envelope (E) proteins entirely protected mice against ZIKV-induced testis and sperm damage. New research using pregnant rhesus macaques revealed long-standing persistence of ZIKV in both maternal and fetal tissues, enhanced maternal and fetal immune responses, and fetal inflammation. It is not yet clear if pathologic effects are different or more severe among immunocompromised persons. Given ZIKV pathogenesis and cell and tissue tropism, there is an urgent need to develop Zika vaccines that have the potential to protect the public—especially pregnant women and their fetuses—from ZIKV infection.

ZIKAVIRUS
Zika is an emerging, mosquito-borne, enveloped, nonsegmented, 10-kilobase, single-stranded, positive-sense RNA flavivirus of global significance. Three main genetic lineages of ZIKV (2 from Africa [African I and African II lineages] and 1 from Asia) have been identified. Genetic analyses indicate that its geographic circulation was limited to the areas around Africa and Asia by the 2000s; ZIKV then evolved into 2 distinct lineages with differential pathogenesis—African (ie, African I lineage) and Asian. A study published in July 2018 by Beaver et al revealed that the African lineages were more virulent than the Asian and induced stronger inflammatory responses. However, it is not clear why neurologic disorders and congenital malformations throughout the Americas are mainly associated with the Asian lineage strains. The Asian strains have been found to activate innate immune interferon (IFN) regulatory factors via NS1, NS4B, and NS5 ZIKV nonstructural proteins while African lineage strains have not, demonstrating evolutionary differences in pathogenesis and molecular responses between Asian and African lineages.

The Zika genome is analogous to that of other Flaviviridae RNA viruses (ie, yellow fever, Japanese encephalitis, West Nile, tick-borne encephalitis, and dengue type 1-4 viruses) and encodes for 3 major structural proteins (ie, prM, capsid [C], and E [a primary target of neutralizing antibody development]) and 7 nonstructural proteins (ie, NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). Notably, the nonstructural NS5 protein is implicated in RNA synthesis and viral replication. Importantly, the proteins documented to have significance in terms of immune response include nonstructural protein NS5 that has been shown to suppress type I IFN signaling through STAT2-mediated degradation in the ZIKV-infected host. During viral shedding, prM is cleaved by furin protein to generate mature infectious virions. Zika virus E protein is the main surface protein that participates in host cell receptor attachment and virus lipid bilayer fusion, while the nonstructural NS1 through NS5 proteins are engaged in virus propagation. Robust adaptive immune responses to ZIKV E, NS1, NS3, NS4B, and NS5 proteins such as production of neutralizing antibodies and T-cell responses have been detected in animal models of ZIKV infection, which indicates that vaccination may protect against ZIKV disease.

ISSUES IN VACCINE DEVELOPMENT
The ideal vaccine against Zika would require a single dose, be capable of being...
| Variable                          | Preferred profile                                                                 | Minimal profile                                                                 |
|----------------------------------|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Indication for use              | Prevent clinical illness in individuals ≥9 y                                        |                                                                                 |
| Contraindications                | None for pregnant/lactating women                                                  |                                                                                 |
| Target population                | Women of reproductive age                                                          |                                                                                 |
|                                  | Adolescent girls ≥9 y                                                             |                                                                                 |
|                                  | Boys/men of the same age range                                                    |                                                                                 |
| Exclusions                       | Depends on vaccine platform:                                                      |                                                                                 |
|                                  | Neurologic disorders                                                              |                                                                                 |
|                                  | Autoimmune disorders                                                              |                                                                                 |
|                                  | Immunosuppression                                                                 |                                                                                 |
| Vaccine type                     | Nonreplicating platforms                                                          |                                                                                 |
|                                  | • Inactivate whole virus                                                           |                                                                                 |
|                                  | • Subunit-based                                                                   |                                                                                 |
|                                  | Platforms with licensed vaccines                                                   |                                                                                 |
|                                  | Single-cycle replicating vectors with robust safety data                           |                                                                                 |
|                                  | Live attenuated vaccine or replication competent with safety data                  |                                                                                 |
| Safety/reactogenicity            | Comparable to WHO-recommended vaccines                                            | Tolerable reactogenicity and acceptable safety profile                          |
|                                  | Low risk of high fever                                                            |                                                                                 |
| Efficacy                         | Demonstrated prevention of ZIKV illness                                            | Meets an established surrogate of immunity in animal models or cohort studies (ie, neutralizing Ab titers in >70% of recipients) |
| Dose                             | Single dose                                                                       | Multiple dose                                                                   |
| Durability                       | Long-lasting protection of more than 1 y and can be maintained by a single booster dose | Protection lasts at least 1 y and can be maintained by booster doses           |
| Route                            | Injectable (IM or SC)                                                              |                                                                                 |
| Virus coverage                   | Monovalent with documented neutralization of Asian and African lineages           |                                                                                 |
| Product stability                | At least 12 mo at −20°C                                                            | At least 12 mo at −20°C                                                        |
|                                  | At least 6 mo at 2°-8°C                                                            | Stability for 6 h at 2°-8°C                                                     |
| Coadministration with other vaccines | Can be administered with other vaccines with no loss of immunogenicity or safety | Stand-alone vaccine                                                             |
| Presentation and packaging       | Liquid product in single-dose or multidose packages. Maximal volume of 0.5 mL     | Lyophilized product in single-dose or multidose packages. Maximal volume of 0.5 mL |

Ab = antibody; IM = intramuscular; SC = subcutaneous; WHO = World Health Organization; ZIKV = Zika virus.

Data from the World Health Organization.47
administered to anyone regardless of age or medical condition (including pregnancy), result in durable (if not lifelong) immunity, prevent medically significant outcomes of infection in both the immediate recipient (eg, GBS) and in the fetus (eg, microcephaly and other congenital conditions), be safe and highly effective, and ideally not require either a cold chain or complex logistics to store and administer. Given the observation of intermittent outbreaks thus far, the ability to store vaccine stockpiles for long periods of time is also necessary. Such a product profile has yet to be achieved for any vaccine. The WHO has defined a more limited target product profile (Table 1), at least for a first-generation vaccine product.\textsuperscript{47} Vaccine development will also face several challenges, including the lack of an established correlate of protection (in children, adults, and the fetus), current unpredictability and lack of outbreaks, the large number of subclinical infections, the marked variability in clinical manifestations during symptomatic illness, the need to test multiple vulnerable populations, the uncertain effects of prior immunity to ZIKV or other flaviviruses (ie, DENV), and the lack of animal models that recapitulate important features of human disease.\textsuperscript{48} These and other factors have been discussed in a recent WHO landscape analysis.\textsuperscript{49}

### Zika Immunology

Both type I and type III IFNs are produced in response to ZIKV infection and can limit viral replication.\textsuperscript{50} Zika virus proteins can actively inhibit the IFN response during infection.\textsuperscript{51} As we learn more details about these virus-host interactions, the results may provide important information regarding appropriate adjuvant selection for vaccine candidates. Many of the animal models used for ZIKV work have defects in innate immune pathways; therefore, results must be interpreted with caution, as they may not reflect what will occur in humans. Nonhuman primate, guinea pig, and chicken embryo models are also being developed, as are models to study vaccine outcomes in pregnancy.\textsuperscript{31,52-55} Efforts are also under way to develop a controlled human infection model for Zika, much like what has been done with influenza, malaria, and DENV.\textsuperscript{60}

The adaptive immune response to flaviviruses (including ZIKV) involves both humoral and cell-mediated components. Neutralizing antibody (considered a major contributor to protective immunity) responses target the E protein and are cross-reactive with other flaviviruses.\textsuperscript{37-39} This cross-reactivity has been an issue for diagnostic tests in areas where diseases such as dengue fever, West Nile virus, and yellow fever are endemic. In these geographic areas, coinfection with multiple flaviviruses is common and represents a complication in terms of immune response analysis that must be considered during the development and deployment of a ZIKV vaccine.\textsuperscript{60}

Monoclonal antibody treatment protects mice against infection,\textsuperscript{61} and depletion of T cells in previously vaccinated animals does not abrogate protective immunity.\textsuperscript{52} These experiments suggest that humoral immunity can protect against disease and that vaccine-induced immunity can be protective. Despite this, there are several questions that remain unanswered: (1) in DENV, suboptimal antibody responses can enhance disease severity—a phenomenon known as antibody-dependent enhancement (ADE), and we do not know if ADE could also be an issue for ZIKV vaccines as it has been in the use of DENV vaccines; (2) vaccine responses are likely to be quite different in individuals who have no prior exposure to Zika or other flaviviruses compared with those with preexisting immunity, and these population groups may require fundamentally different vaccine formulations for both safety and optimal protection; and (3) it is likely that optimal humoral responses to ZIKV will require T-cell help, and a solitary focus on antibody titers as the only immunologic end point may be counterproductive.
Dengue virus infection also serves as a good model of cellular immunity to ZIKV. Robust T-cell responses develop after DENV infection, with CD4⁺ T-cell responses targeting the C, E, and NS1 proteins while CD8⁺ T-cell responses preferentially target the nonstructural proteins.63,64 In contrast, for ZIKV, CD4⁺ and CD8⁺ T-cell epitopes have also been found in the prM, C, and E proteins.65 This has also been observed for Japanese encephalitis virus.66 In a mouse model, both vaginal and subcutaneous infection with ZIKV led to the proliferation of virus-specific T cells.67 Adoptive transfer of these T cells into naive mice led to a significant reduction in viral titers upon infection, indicating that T-cell responses contribute to protective immunity. The evidence thus far suggests that an optimal vaccine would elicit both humoral and cellular immunity.

**Vaccine Indications and Target Audience**

Although Zika infection typically causes no or self-limited symptoms, more severe symptomatology can and does occur. This may be particularly true in pregnant women and women of childbearing age, infants/children, older adults, and those who are immunocompromised. Given the destructive fetal effects of Zika infection and the need to protect unborn children, it seems reasonable that the group requiring the most immediate protection is women, followed by men, of childbearing potential. This will likely be followed by the desire and need to protect all ages. Guillain-Barré syndrome may be particularly more likely and severe among older adults, and hence this represents a different spectrum of risk group. Such considerations may drive vaccine development efforts. For example, women who are pregnant cannot receive a live virus vaccine, while older immunosenescent adults may require vaccine adjuvants to boost immune response.

**Ethical Issues**

While not the intent of this review, we briefly comment on ethical issues related to vaccine development and policy. A significant ethical issue is how and under what conditions should pregnant women be included in Zika vaccine trials, given the unknown possible effects on the unborn developing child. Recent opinions on this question have been published.68 Other issues include how to provide vaccine to those in lower income countries who cannot afford it and, given historic new vaccine pricing, how a vaccine can be utilized in poorer countries where outbreaks may occur. If vaccine supplies are limited, who shall be prioritized?

**Animal Testing**

Animal models provide an important testing ground for developing new vaccines. With the obvious caveat that these are models that only partially recapitulate human anatomy, physiology, and immune response, animal models of infection provide important insights because capturing the complexity and systemic interactions required for immune function requires a living organism. These models provide complete control over baseline characteristics (eg, age, sex, pregnancy status, preexisting immunity), timing and dose of infection, sampling time points, biospecimen collection (eg, blood, tissues, organs), and the ability to examine gonadal tissues and products of conception.

Mouse models are inexpensive, are available on multiple genetic backgrounds, are conducive to large sample sizes, and have a vast array of relevant immunologic tools (ie, antibodies and sequence information) available. Mouse models of ZIKV infection are relatively common, and a number of strains have been used to examine aspects of ZIKV disease.69 Zika virus has variable replication efficiency in wild-type mouse strains (BALB/c greater than C57BL/6) but does not produce clinical illness in adult mice. Disruption of IFN responses is required for disease manifestations. The most common models are inbred strains on the 129 background that lack the IFNAR1 (A129) or both the IFNAR1 and IFNGR1.
| Institute/company                      | Status                  | Vaccine(s) platform(s)                                                                 |
|---------------------------------------|-------------------------|---------------------------------------------------------------------------------------|
| Inovio Pharmaceuticals, Inc           | In phase 1 clinical trials | DNA vaccine                                                                            |
| NIH                                   | In phase 1 clinical trials | DNA vaccine, Live VSV recombinant (early R&D), Live attenuated ZIKV (early R&D)        |
| WRAIR/Sanofi Pasteur Limited          | In phase 1 clinical trials | Whole, purified, inactivated virus                                                     |
| Butantan Institute                    | In phase 1 clinical trials | Live, DENV-vectored vaccine expressing premembrane/membrane and envelope proteins, Purified inactivated virus |
| Bharat Institute of Science and Technology | Preclinical/animal studies | Purified inactivated virus, VLP-expressing polyprotein                                  |
| NewLink Genetics Corporation          | Preclinical/animal studies | Purified inactivated virus                                                              |
| PaxVax, Inc                           | Preclinical/animal studies | Purified inactivated virus                                                              |
| Novavax, Inc                          | Preclinical/animal studies | Protein nanoparticle vaccine                                                            |
| Replikins Ltd                         | Preclinical/animal studies | Synthetic peptide vaccine                                                               |
| Pharos Biologicals LLC                | Preclinical/animal studies | DNA vaccine                                                                            |
| Bio-Manguinhos                        | Early-stage research     | Purified inactivated virus YF17DD chimera, VLP, DNA                                     |
| US CDC                                | Early-stage research     | VLP expressing ZIKV DNA, Live adenovirus recombinant                                    |
| CureVac AG                            | Early-stage research     | Thermostable mRNA-based vaccine                                                         |
| Geovax Labs, Inc                      | Early-stage research     | Live MVA recombinant                                                                   |
| GlaxoSmithKline plc                   | Early-stage research     | Self-amplifying mRNA platform, Whole, inactivated virus                                 |
| Hawaii Biotech Inc                    | Early-stage research     | Aluminium hydroxide gel (Alhydrogel) + recombinant protein                              |
| University of Oxford                  | Early-stage research     | Live adenovirus recombinant                                                            |
| Protein Sciences Corporation          | Early-stage research     | Recombinant envelope protein                                                           |
| Sanofi                                | Early-stage research     | YF17D chimera                                                                          |
| Sementis                              | Early-stage research     | Live poxvirus recombinant                                                              |
| Themis Bioscience GmbH                | Early-stage research     | Live measles recombinant                                                                |
| Valneva SE                            | Early-stage research     | Purified inactivated virus                                                             |
| Mayo Clinic Vaccine Research Group    | Early-stage research     | Naturally processed and HLA-presented ZIKV peptides packaged with biodegradable nanoparticles |
| Moderna, Inc                          | Early-stage research     | Lipid nanoparticle—delivered mRNA                                                      |
| Emergent BioSolutions Inc             | Early-stage research     | Inactivated, whole virus                                                                |
| Institut Pasteur of Shanghai          | Early-stage research     | Recombinant subunit VLP                                                                 |
| Takeda Pharmaceutical Company Limited | Early-stage research     | Alum adjuvanted, inactivated whole virus                                                |
| Edward Jenner Institute for Vaccine Research | Early-stage research | Simian adenovirus vector                                                               |
| VBI Vaccines Inc                      | Early-stage research     | VLP containing envelope and NS1 proteins                                                |
| Vaxart, Inc                           | Early-stage research     | Recombinant oral vaccine                                                                 |

**Note:** CDC = Centers for Disease Control and Prevention; DENV = dengue virus; mRNA = messenger RNA; MVA = modified vaccinia virus ankara; NIH = National Institutes of Health; R&D = research and development; VLP = virus-like particles; VSV = vesicular stomatitis virus; WRAIR = Walter Reed Army Institute of Research; ZIKV = Zika virus.
(AG129) and a strain on the B6 background lacking IFNAR1. Severe combined immunodeficiency mice also develop disease but at a delayed rate compared with AG129. Mice lacking INF response factors (IRFs) (eg, IRF3, IRF5, IRF7) also exhibit disease symptoms on experimental infection. Unfortunately, the immunosuppressed nature of these animals complicates vaccine development and testing. The use of INF receptor–blocking antibodies can be utilized in wild-type mice to recapitulate disease susceptibility. The use of neonatal mice and/or intracranial inoculation can produce some disease symptoms (eg, neurologic signs or paralysis). A model of intrauterine infection has been established in Swiss Jim Lambert (SJL) mice.

Although immune responses to ZIKV have been detected in a large number of larger animals (water buffalo, goats, lions, sheep), nonhuman primates are the model of choice for ZIKV research. Rhesus and cynomolgus macaques are most commonly used. Clinical symptoms include erythema, fever, and lymphadenopathy, and virus can be found in multiple body fluids. New World monkeys have more severe clinical symptoms after flavivirus infection than Old World monkeys and may represent a more restrictive animal model. It should be noted that different ZIKV strains induce different symptoms in different animals, suggesting that human disease manifestations may also be strain-dependent. The nonhuman primate studies have provided important insights into ZIKV immunity, as well as efficacy testing for developmental vaccines. Together with the mouse strains, these animal models will continue to be useful platforms for testing and evaluating ZIKV vaccines.

CURRENT STATUS OF VACCINE DEVELOPMENT

The recent outbreaks of ZIKV in the Pacific and South America significantly heightened public health awareness of Zika as well as increased research interest in Zika virology, pathology, epidemiology, and immunology. In March 2016, the WHO reported 18 ZIKV vaccine programs, and the number may have grown since then. A wide variety of formulations are being studied; among those being tested are live virus vaccines, inactivated vaccines, whole-virus vaccines, subunit vaccines, and messenger RNA (mRNA)—, DNA-, protein-, and vector-based formulations. Table 2 lists the most developed of these candidates. Herein, we will highlight a few of the vaccine approaches.

The Walter Reed Army Institute of Research has developed a whole-virus, formalin-inactivated vaccine. This vaccine has been tested with and without alum, utilizing multiple immunization routes, and in both mice and nonhuman primates. Vaccination elicits high-titer neutralizing antibodies as well as cellular immune responses and produces sterile immunity in rhesus macaques. This vaccine has undergone phase 1 clinical trials (ClinicalTrials.gov Identifier: NCT02937233, NCT02952833, NCT02963909), and another phase 1, dose escalation study examining safety and immunogenicity is ongoing (NCT03008122). The results from the first 3 trials indicate that recipients developed robust neutralizing antibody titers that on transfer into mice significantly reduced or eliminated viral titers following ZIKV challenge. Adverse effects were reported by 84% of recipients but were relatively minor (eg, pain or tenderness at injection site, fatigue, headache, malaise).

rZIKV/D4Δ30-713 is a live attenuated vaccine being tested in flavivirus-naive adults (NCT03611946). This vaccine is constructed on the backbone of DENV serotype 4 and expresses ZIKV surface proteins. The virus vector has been attenuated through the deletion of a 30 nucleotide sequence in the 3′ untranslated region that drastically reduces viral replication. The resulting vaccine vector has been administered to rhesus macaques and to humans with no serious adverse events reported. In addition to
protein and live virus vaccines, a number of nucleic acid vaccines have demonstrated promising results.

Messenger RNA 1325 (NCT03014089) is a non–self-amplifying mRNA-based vaccine expressing a prM-E protein. The antigen sequence has been modified to remove epitopes in regions known to contribute to DENV ADE. Uridines have also been replaced with 1-methylpseudouridine in order to avoid innate immune responses to the nucleic acid backbone. AG129 mice developed neutralizing antibody following a single vaccination, and those titers increased significantly after a booster immunization. Animals receiving 10 μg of vaccine (with or without the booster immunization) were protected against a lethal ZIKV challenge. A lower vaccine dose (2 μg) resulted in 60% protection after a single immunization and 90% protection after a prime-boost immunization. The effects of the vaccine in immunocompetent mice (C57BL/6) were also studied. Neutralizing antibody titers were low but detectable after a single immunization and were significantly increased following the booster immunization. Mice were pretreated with IFNAR-blocking antibody and then challenged with ZIKV (Dakar 41519). Unimmunized mice developed high levels of viremia, lost weight, and experienced a 25% to 30% mortality rate following challenge. In contrast, mice given a prime-boost immunization exhibited no viremia, no weight loss, and 100% survival. These studies also demonstrated that removal of the E-DII-FL epitope thought to be involved in ADE did not affect the development of neutralizing antibodies or vaccine-induced protection.

A similar mRNA-based vaccine also incorporates a modified nucleoside (1-methylpseudouridine) and encodes the prM-E glycoproteins of the H/PF/2013 strain of ZIKV. This vaccine construct contains modified nucleosides intended to boost antigen production and reduce innate immune responses to the construct. Mouse studies revealed that the vaccine elicited neutralizing antibody, antigen-specific CD4+ T-cell responses and protected against viral challenge. Vaccination of nonhuman primates (rhesus macaques) resulted in the development of E protein–binding antibody and neutralizing antibody, and 80% of immunized animals were protected against viral challenge (ie, no detectable viremia).

MV-ZIKA, a recombinant measles virus expressing the prM and E proteins (NCT02996890), has been developed by Themis Bioscience GmbH. This construct is based on the measles virus vaccine backbone, which is an approach that has also shown promise with chikungunya virus. The measles vaccine has an excellent safety record and results in robust immunity to measles. It is hoped that these characteristics are retained when novel antigens are added to the measles vaccine virus genome.

The most advanced vaccine candidates to date include VRC-ZKADNA090-00-VP, a plasmid-based DNA vaccine encoding the prM and E proteins of a French Polynesian strain of ZIKV (H/PF/2013). It is currently undergoing a phase 2 clinical trial in healthy adults aged 18 to 35 years (NCT03110770), along with VRC-ZKADNA085-00-VP, a similar DNA-based plasmid vaccine also encoding the prM and E proteins of the H/PF/2013 strain of ZIKV (NCT02840487). Animal studies demonstrated that these vaccine candidates were highly immunogenic in BALB/c and C57BL/6 mice, eliciting high-titer neutralizing antibodies at 2-, 10-, and 50-μg doses. A 2-dose vaccination schedule in rhesus macaques elicited virus-binding and virus-neutralizing antibody responses. The vaccines also reduced—and, in some animals, eliminated—viremia after viral challenge. The study also found a correlation between protection from challenge- and prechallenge-neutralizing antibody titer.

VLA1601 is a purified, inactivated, whole-virus, alum-adsorbed vaccine being
tested in flavivirus-naive adults (NCT03425149). Early study results indicate that the vaccine elicits neutralizing antibodies in a dose- and schedule-dependent manner. This vaccine was developed using the same platform as the IXIARO Japanese encephalitis vaccine.

After 2016, the number of ZIKV cases has decreased to the point that phase 3 field trials of the previously mentioned vaccines may be difficult or impossible to conduct. Nevertheless, evaluating the effectiveness of these and other vaccine candidates is essential if we are to be prepared for a reemergence of the virus. This reemergence may occur in regions with prior epidemics once population immunity wanes and/or among naive populations due to shifts in geographic range of the Aedes vectors. Governmental agencies such as the US Food and Drug Administration and the European Medicines Agency are exploring pathways for regulatory approval that provide the needed flexibility to address ZIKV-specific considerations.

A wide variety of other preclinical-stage vaccine candidates are currently being developed. The Mayo Clinic Vaccine Research Group is using an established mass spectrometry approach to isolate ZIKV-derived peptides from infected cells for use as a peptide-based vaccine. Peptide-based vaccines have a number of significant advantages that would be ideally suited for use as a ZIKV vaccine: inexpensive to manufacture, safe for universal administration, no cold chain requirements, easily stored and administered, can contain T- and/or B-cell epitopes, and have a defined epitope selection in order to avoid ADE. Preclinical studies utilizing such peptides in combination with biodegradable nanoparticles in mice are currently in progress.

EXPERT COMMENTARY AND A LOOK AHEAD

We believe that safe and effective Zika vaccines can be developed and approved; however, major concerns exist. First, because Zika outbreaks have essentially ceased and are unpredictable, it is likely that vaccine development may be stalled and timely efforts curtailed. Recently, the results of a WHO/National Institutes of Health conference on this issue have been published. This problem may require the use of the Food and Drug Administration animal rule, human challenge studies, passive transfer animal studies, and other methods in order to continue to advance vaccine development and licensure.

Historically, such has been the case when an emerging pathogen causes substantial concern and threatens public health, emergency funding from governments results, only to not be sustained as the epidemic wanes. The recent lessons of severe acute respiratory syndrome, Middle East respiratory syndrome, Lassa fever, and to a lesser extent Ebola and others, loom large in this regard. When financial costs and profit are uncertain, the private sector will be reluctant to invest the magnitude of dollars necessary to bring such a vaccine to the point of licensure. If so, sustainable models for funding must be developed before the next large outbreaks of Zika.

Second, given current realities, it is likely that more than one Zika vaccine type may need to be developed. For example, an inactivated vaccine will be required for pregnant women and perhaps women of childbearing age. Live attenuated vaccines could be deployed in children, males, and older adults. Higher-potency or adjuvanted vaccines may be needed for the immunosenescent elderly and those who are immunocompromised. DNA- or vector-based vaccines may prove more immunogenic and result in longer-lasting immunity.

Third, more research is necessary to determine what the Zika infection outcomes of interest are that we want vaccine to prevent. Is it GBS? Zika congenital conditions? Latent infection and persistence in gonadal organs? Other? Fourth, issues of vaccine-induced immunity are significant. How many doses will be required and over what time periods?
How durable and long-lasting will vaccine-induced immunity be? Are there risks for ADE in humans resulting in inadvertent harm? Fifth, ethical issues such as human challenge studies that include pregnant women in vaccine development clinical trials and include children in clinical trials, among others, must be defined. These and other important questions remain and must be solved. Although we believe they are solvable, it may require considerable time—even decades—to do so. In the meantime, the most advanced candidate vaccine in clinical development appears to be the National Institutes of Health-developed vaccine. It is likely, assuming no safety concerns arise in future phase 3 studies, that this vaccine will be the first licensed. This is likely to be followed by additional vaccines and effective antiviral drugs to treat and prevent infection over the short term.

CONCLUSION
Public health urgency, advances in genetics-based design of vaccines, and newer insights in immunology have combined to accelerate vaccine development against Zika virus. Multiple vaccine candidates are already in preclinical through phase 2 studies, with some poised to enter phase 3 studies of efficacy. This is remarkable given the fact that Zika virus went relatively unnoticed until the large outbreaks in Brazil starting in 2016. On the positive side, this extraordinary progress has resulted from collaborations among academia, biotech start-ups, pharmaceutical companies, nongovernmental organizations, and a variety of funders. On the negative side, inadequate research funding, late funding given the initial outbreaks in the Yap Islands in 2007, and a variety of difficulties in moving vaccine candidates down the development pipeline, have slowed progress. In particular, governments must invest the research and development dollars and provide industry incentives for rapid clinical development to occur. This must be a shared burden but should particularly have intense and sustained involvement by the countries where mosquito abatement has been “too little too late” and where outbreaks of this disease have developed. Additionally, these outbreaks are an excellent example of the need for a global funding entity—as called for in a recent publication. It is likely that in the private sector, the costs of Zika vaccine development cannot be recouped due to the relative lack of current and ongoing large-scale outbreaks. Thus, industry will need incentives or government-provided development dollars to invest resources into the multimillion dollar enterprise needed to advance a vaccine candidate through to approval by regulatory authorities.

In the meantime, limited history thus far suggests that ZIKV outbreaks can strike and abate relatively rapidly, with limited ability to predict where the next outbreak(s) will occur. Other unknowns include possible further mutational divergence of strains and the development of new Zika clades that may require more than a monotypic vaccine for full protection. Lastly, thoughtful decisions must be made regarding whom and with what priority different groups should receive vaccine, at what ages, and to prevent which outcomes. Other issues such as whether pregnant women can be enrolled in vaccine studies and receive specific vaccine types will need to be debated and considered.

The health and well-being of the globe requires a safe and effective Zika vaccine. For couples of childbearing age desiring to have children, the prospect of Zika infection is terrifying. Maternal infections can and do lead to a spectrum of congenital consequences—some of which are severe and much of which is yet to be fully unraveled. The global community must pay attention and remain undeterred by the tyranny of the next urgency that detracts attention away from the goal of a vaccine. It is not simply an infection “over there”—this is a global issue that requires a global solution. The future and health of the most vulnerable among us—the yet unborn—depends on our efforts.

ACKNOWLEDGMENTS
We thank Caroline L. Vitse for her editorial assistance in preparing the submitted manuscript.
Potential Competing Interests: Dr Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories and is a consultant on vaccine development to Merck & Co. Inc, Avianax LLC, Adjuvance, Valneva SE, Medicago Inc, Sanofi Pasteur Limited, GlaxoSmithKline plc, and Emergent Biosolutions Inc. Drs Poland and Ovsyannikova hold 3 patients related to vaccinia and measles peptide vaccines Dr Kennedy holds a patent related to vaccinia peptide vaccines. BioSolutions Inc. Drs Poland and Ovsyannikova hold 3 patents related to vaccinia and measles peptide vaccines. Dr Kennedy holds a patent related to vaccinia peptide vaccines.

Published Online: Accessory: Gregory A. Poland, MD, Director, Mayo Clinic Vaccine Research Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (poland.gregory@mayo.edu).

The Thematic Reviews on Vaccines will continue in an upcoming issue.

REFERENCES

1. Lowe R, Barcelos C, Brasil P, et al. The Zika virus epidemic in Brazil: from discovery to future implications. Int J Environ Res Public Health. 2018;15(1):96.
2. Plotkin SA, Mahmoud AA, Farrar J. Establishing a global vaccine-development fund. N Engl J Med. 2015;373(4):297–300.
3. Centers for Disease Control and Prevention. Zika virus: statistics and maps. https://wwwnc.cdc.gov/travel/zika/travel-information. Updated May 15, 2019. Accessed March 29, 2019.
4. Leta S, Beyene TJ, De Clercq EM, Ameru K, Kraemer MUG, Revie CW. Global risk mapping for major diseases transmitted by Aedes aegypti and Aedes albopictus. Int J Infect Dis. 2018;67:25–35.
5. Panchaud A, Stojanov M, Ammerdorffer A, Vouga M, Baud D. Post-exposure prophylaxis for Zika virus in adverse fetal and neonatal outcomes. Clin Microbiol Rev. 2016;29(3):659–694.
6. Alvarado MG, Schwartz DA. Zika virus infection in pregnancy, microcephaly, and maternal and fetal health: what we think, what we know, and what we think we know. Arch Pathol Lab Med. 2017;141(1):26–32.
7. Dick GW, Kitchen SF, Haddow AJ. Zika virus, I: Isolations and antigenic properties of a new Dengue virus-like agent from New Guinea. Nature. 1952;169(4259):335–336.
8. WHO. Zika situation report. https://www.who.int/zika/situation-reports/zika-virus. Updated May 15, 2019. Accessed March 29, 2019.
9. Jansson MA, Meer YT, Reehuis j, Glibba SM, Hills SL, Zika and the risk of microcephaly. [published correction appears in N Engl J Med. 2016;375(5):498]. N Engl J Med. 2016;375(1):1–4.
10. Bogoch II, Brady OJ, Kraemer MUG, et al. Anticipating the international spread of Zika virus from Brazil. Lancet. 2016;387(10065):335–336.
11. World Health Organization. Zika virus. https://www.who.int/news-room/fact-sheets/detail/zika-virus. Published July 20, 2018. Accessed March 29, 2019.
12. World Health Organization. Zika virus. https://www.who.int/csr/don/8-february-2016-gbs-brazil/en/. Published February 12, 2016. Accessed March 29, 2019.
13. World Health Organization. Guillain-Barré syndrome — Brazil. https://www.who.int/emergencies/zika-virus/situation-reports/who-zika-situation-report-12-02-2016.pdf?ua=1. Published February 12, 2016. Accessed March 29, 2019.
14. World Health Organization. Guillain-Barré syndrome — Brazil. https://www.who.int/csr/don/8-february-2016-gbs-brazil/en/. Published February 8, 2016. Accessed March 28, 2019.
15. Gschott F, Puhan M, Hatz C, Schlenkhaupf P. Non-vector-borne transmission of Zika virus: a systematic review. Travel Med Infect Dis. 2016;14(4):313–330.
16. Mead PS, Duggal NK, Hook SA, et al. Zika virus shedding in pregnant women: what we know, and what we think we know. Arch Pathol Lab Med. 2017;141(1):26–32.
17. Barbi L, Coelho AVC, Alencar LCA, Crovella S. Prevalence of Guillain-Barré syndrome among Zika virus infected cases: a systematic review and meta-analysis. Braz J Infect Dis. 2018;22(2):137–141.
18. Rocklöv J, Quam MB, Sudre B, et al. Assessing seasonal risks for the introduction and mosquito-borne spread of Zika virus in Europe. EBioMedicine. 2016;9:250–256.
19. Plotkin SA, Mahmoud AA, Farrar J. Establishing a global vaccine-development fund. N Engl J Med. 2015;373(4):297–300.
20. Centers for Disease Control and Prevention. Zika virus: statistics and maps. https://wwwnc.cdc.gov/travel/travel-information/zika?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fzika%2F.travel-information. Updated May 15, 2019. Accessed March 29, 2019.
21. Leta S, Beyene TJ, De Clercq EM, Ameur K, Kraemer MUG, Revie CW. Global risk mapping for major diseases transmitted by Aedes aegypti and Aedes albopictus. Int J Infect Dis. 2018;67:25–35.
22. World Health Organization. Zika virus. https://www.who.int/news-room/fact-sheets/detail/zika-virus. Published July 20, 2018. Accessed March 29, 2019.
23. Jansson MA, Meer YT, Reehuis j, Glibba SM, Hills SL, Zika and the risk of microcephaly. [published correction appears in N Engl J Med. 2016;375(5):498]. N Engl J Med. 2016;375(1):1–4.
24. Panchaud A, Stojanov M, Ammerdorffer A, Vouga M, Baud D. Post-exposure prophylaxis for Zika virus in adverse fetal and neonatal outcomes. Clin Microbiol Rev. 2016;29(3):659–694.
25. Alvarado MG, Schwartz DA. Zika virus infection in pregnancy, microcephaly, and maternal and fetal health: what we think, what we know, and what we think we know. Arch Pathol Lab Med. 2017;141(1):26–32.
26. Barbi L, Coelho AVC, Alencar LCA, Crovella S. Prevalence of Guillain-Barré syndrome among Zika virus infected cases: a systematic review and meta-analysis. Braz J Infect Dis. 2018;22(2):137–141.
27. World Health Organization. Zika virus. https://www.who.int/csr/don/8-february-2016-gbs-brazil/en/. Published February 12, 2016. Accessed March 29, 2019.
28. World Health Organization. Guillain-Barré syndrome — Brazil. https://www.who.int/emergencies/zika-virus/situation-reports/who-zika-situation-report-12-02-2016.pdf?ua=1. Published February 12, 2016. Accessed March 29, 2019.
29. World Health Organization. Guillain-Barré syndrome — Brazil. https://www.who.int/csr/don/8-february-2016-gbs-brazil/en/. Published February 8, 2016. Accessed March 28, 2019.
30. Gschott F, Puhan M, Hatz C, Schlenkhaupf P. Non-vector-borne transmission of Zika virus: a systematic review. Travel Med Infect Dis. 2016;14(4):313–330.
31. Mead PS, Duggal NK, Hook SA, et al. Zika virus shedding in pregnant women: what we know, and what we think we know. Arch Pathol Lab Med. 2017;141(1):26–32.
32. World Health Organization. Zika virus situation report. https://www.who.int/emergencies/zika-virus/situation-reports/who-zika-situation-report-12-02-2016.pdf?ua=1. Published February 12, 2016. Accessed March 29, 2019.
33. World Health Organization. Guillain-Barré syndrome — Brazil. https://www.who.int/emergencies/zika-virus/situation-reports/who-zika-situation-report-12-02-2016.pdf?ua=1. Published February 12, 2016. Accessed March 29, 2019.
34. Gschott F, Puhan M, Hatz C, Schlenkhaupf P. Non-vector-borne transmission of Zika virus: a systematic review. Travel Med Infect Dis. 2016;14(4):313–330.
35. Mead PS, Duggal NK, Hook SA, et al. Zika virus shedding in pregnant women: what we know, and what we think we know. Arch Pathol Lab Med. 2017;141(1):26–32.
36. World Health Organization. Zika virus. https://www.who.int/csr/don/8-february-2016-gbs-brazil/en/. Published February 8, 2016. Accessed March 28, 2019.
37. World Health Organization. Guillain-Barré syndrome — Brazil. https://www.who.int/emergencies/zika-virus/situation-reports/who-zika-situation-report-12-02-2016.pdf?ua=1. Published February 12, 2016. Accessed March 29, 2019.
38. World Health Organization. Guillain-Barré syndrome — Brazil. https://www.who.int/emergencies/zika-virus/situation-reports/who-zika-situation-report-12-02-2016.pdf?ua=1. Published February 12, 2016. Accessed March 29, 2019.
39. World Health Organization. Guillain-Barré syndrome — Brazil. https://www.who.int/emergencies/zika-virus/situation-reports/who-zika-situation-report-12-02-2016.pdf?ua=1. Published February 12, 2016. Accessed March 29, 2019.
40. Griffin BD, Muthumuni K, Warner BM, et al. DNA vaccination protects mice against Zika virus-induced damage to the testes. Nat Commun. 2017;8:15743.
41. Hirsch AJ, Roberts VHJ, Grigoly PL, et al. Zika virus infection in pregnant rhesus macaques causes placental dysfunction and immunopathology. Nat Commun. 2018;9(1):263.
32. Poland GA, Kennedy RB, Ovsyannikova IG, Palacios R, Ho PL, Kalij L. Development of vaccines against Zika virus. Lancet Infect Dis. 2018(8):e211-e219.

33. Shen S, Shi J, Wang J, et al. Phylogenetic analysis revealed the central roles of two African countries in the evolution and worldwide spread of Zika virus. Virol. 2016;31(2):118-130.

34. Lanciotti RS, Lambert AJ, Holodniy M, Saavedra S, Signor Ldel C. Phylogeny of Zika virus in Western Hemisphere, 2015. Emerg Infect Dis. 2016;22(5):933-935.

35. Taguarelli U, Ullota S, Villagra E, et al. A report on the outbreak of Zika virus on Easter Island, South Pacific, 2014. Arch. Virol. 2016;161(3):665-668.

36. Fauci AS, Morens DM. Zika virus in the Americas—yet another arbovirus threat. N Engl J Med. 2016;374(7):601-604.

37. Smith DR, Sprague TR, Holldige BS, et al. African and Asian Zika virus isolates display phenotypic differences both in vitro and in vivo. Am J Trop Med Hyg. 2018(9):432-444.

38. Faria NR, Azevedo RD, Kramer M, et al. Zika virus in the Americas: early epidemiological and genetic findings. Science. 2016;352(6283):345-349.

39. Beaver JT, Lelutiu N, Habib R, Skountzou I. Evolution of two major Zika virus lineages: implications for pathology, immune response, and vaccine development. Front. Immunol. 2018;9:1640.

40. Wang L, Zhao H, Oliva SM, Zhu H. Modeling the transmission and control of Zika in Brazil. Sci Rep. 2017;7(1):7271.

41. Mlsdinich MC, Schwedes J, Mackow ER. Zika virus persistently infects and is basolaterally released from primary human brain microvascular endothelial cells. MBio. 2017;8(4).

42. Grant A, Pania SS, Tripathi S, et al. Zika virus targets human STAT2 to inhibit type I interferon signaling. Cell Host Microbe. 2016(19)(6):882-890.

43. Winkler CW, Myers LM, Woods TA, et al. Adaptive immune responses to Zika virus are important for controlling virus infection and preventing infection in brain and testes. J Immunol. 2017;198(9):3526-3535.

44. Pardy RD, Rajah MM, Condotta SA, Taylor NG, Sagan SM, Richer MJ. Analysis of the T cell response to Zika virus and identification of a novel CD8+ T cell epitope in immunocompetent mice. PLoS Pathog. 2017;13(2):e1006184.

45. Pardi N, Hogan MJ, Pelc RS, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543(7649):248-251.

46. Braut AC, Donni A, McDonald EM, et al. A Zika virus targeting NP151S potentiates immunocompetent adult mice in a lethal challenge model. Sci Rep. 2017;7(1):14769.

47. World Health Organization. Zika virus vaccine product development. https://who.int/immunization/research/development/zika/en/. Accessed March 29, 2019.

48. Vannice KS, Cassetti MC, Esinger RW, et al. Demonstrating vaccine effectiveness during a waning epidemic: a WHOINNHL meeting report on approaches to development and licensure of Zika virus candidate. Vaccine. 2019;37(6):863-868.

49. Wilder-Smith A, Vannice K, Durbin A, et al. Zika vaccines and therapeutics: landscape analysis and challenges ahead. BMJ. 2018(6):1384.

50. Lazeru HM, Govero J, Smith AM, et al. A mouse model of Zika virus pathogenesis. Cell Host Microbe. 2016;19(5):720-730.

51. Bowler R, Zimmerman MG, Suthar MS. Taking the defensive: immune control of Zika virus infection. Virol. 2018;254:21-26.

52. Martinot AJ, Abbnink P, Macan O, et al. Fetal neuropathology in Zika virus-infected pregnant female rhesus monkeys. Cell. 2018;173(5):1111-1122.e10.

53. Mohr EL, Block LN, Newman CM, et al. Ocular and uteroplacental pathology in a macaque pregnancy with congenital Zika virus infection, PLoS One. 2018;13(1):e0190617.

54. Kumar M, Krause KK, Azouz F, Nakano E, Nenukar VR. A guinea pig model of Zika virus infection. Virol. 2017;14(1):75-55.

55. Goodfellow FT, Tesia B, Simchick G, et al. Zika virus induced mortality and microcephaly in chicken embryos. Stem Cells Dev. 2016;25(22):1691-1697.

56. Shah SK, Kimmelman J, Lyrer A, et al. Ethical considerations for Zika virus human challenge trials: report and recommendations. https://www.niaid.nih.gov/sites/default/files/EthicsZika-humanChallengeStudiesReport2017.pdf. Published February 2017. Accessed March 29, 2019.

57. Dai L, Song J, Lu X, et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe. 2016;19(5):696-704.

58. Sapparapu G, Fernandez E, Kose N, et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature. 2016;540(7633):443-447.

59. Priyamvada L, Quicke KM, Hudson WH, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A. 2016;113(28):7852-7857.

60. Rodriguez-Moraes AJ, Villamil-Gómez WE, Franco-Paredes C. The arboviral burden of disease caused by co-circulation and co-infection of dengue, chikungunya and Zika in the Americas. Travel Med Infect Dis. 2016;14(3):177-179.

61. Zhao H, Hernandez E, Dowd KA, et al. Structural basis of Zika virus-specific antibody protection. Cell. 2016;166(4):1016-1027.

62. Larocca RA, Abbink P, Peron JP, et al. Vaccine protection against Zika virus from Brazil. Nature. 2016;536(7617):474-478.

63. Wieskopf D, Angelo MA, de Azevedo EL, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A. 2013;10(102):E2046-E2053.

64. Roth C, Delgada FG, Simon-Lorière E, Sakuntabhai A. Immune responses to dengue and Zika viruses—guidance for T cell vaccine development. Int J Environ Res Public Health. 2018;15(2):385.

65. Grifoni A, Pham J, Sidney J, et al. Prior dengue virus exposure shapes T cell immunity to Zika virus in humans. J Virol. 2017;91(24).

66. Turtle L, Bali T, Buxton G, et al. Human T cell responses to Japanese encephalitis virus in health and disease. Exp Med. 2016;213(7):1331-1352.

67. Scott JM, Lebratti TJ, Richner JM, et al. Cellular and humoral immunity protect against vaginal Zika virus infection in mice. J Virol. 2018;92(7).

68. Ethics Working Group on ZIKV Research & Pregnancy, Pregnancy Women & the Zika Virus Vaccine Research Agenda: Ethics Guidance on Priorities, Inclusion, and Evidence Generation. http://guidancezikapregnancyethics.org/wp-content/uploads/2017/08/FLU+Guidance-Pregnant-Women-the-Zika-Virus-Vaccine-Research-Agenda_optimizedpdf. Published June 2017. Accessed March 29, 2019.

69. Bradley MP, Nagramine CM. Animal models of Zika virus. Comp Med. 2017;67(3):242-252.

70. Cugolra FR, Fernandes IR, Russo FB, et al. The Brazilian Zika virus strain birth defects in experimental models. Nature. 2016;534(7606):267-271.

71. Joogt G, Mansuy JM, Matsuii G, et al. Effect of acute Zika virus infection on sperm and virus clearance in body fluids: a prospective observational study. Lancet Infect Dis. 2017;17(11):1200-1208.

72. Julander JG. Animal models of yellow fever and their application in clinical research. Curr Opin Virol. 2016:846-69.

73. Abbink P, Larocca RA, De La Barrera RA, et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science. 2016;353(6304):1129-1132.

74. Modjarrad K, Lin L, George SL, et al. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised,
double-blind, placebo-controlled clinical trials. Lancet. 2018;391(10120):563-571.

75. Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS. Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol. 2006;19(1):10-32.

76. Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3’-untranslated region. Am J Trop Med Hyg. 2001;65(5):405-413.

77. Richner JM, Himansu S, Dowd KA, et al. Modified mRNA vaccines protect against Zika virus infection [published correction appears in Cell. 2017;169(1):176]. Cell. 2017;168(6):1114-1125.e10.

78. Gaudinski MR, Houser KV, Morabito KM, et al. VRC 319 and VRC 320 Study Teams. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet. 2018;391(10120):552-562.

79. Dowd KA, Ko SY, Morabito KM, et al. Rapid development of a DNA vaccine for Zika virus. Science. 2016;354(6309):237-240.

80. Emergent BioSolutions and Valneva report positive phase 1 results for their vaccine candidate against the Zika virus. GlobeNewswire website. http://globenewswire.com/news-release/2018/11/19/1654097/0/en/Emergent-BioSolutions-and-Valneva-Report-Positive-Phase-1-Results-for-Their-Vaccine-Candidate-Against-the-Zika-Virus.html?culture=en-us. Published November 19, 2018. Accessed March 29, 2019.

81. Gruber MF, Farizo KM, Pratt RD, et al. Clinical development strategies and considerations for Zika vaccine licensure. J Infect Dis. 2017;216(suppl 10):S964-S970.